Grade III Astrocytoma

Grade III astrocytoma is a diffuse, fast-growing brain tumor that starts from star-shaped support cells called astrocytes. “Diffuse” means the tumor cells infiltrate normal brain tissue, so the edges are not sharp. In the current World Health Organization (WHO) system, this tumor is called “astrocytoma, IDH-mutant, CNS WHO grade 3.” The older name “anaplastic astrocytoma” has largely been retired, but many doctors still use it. In plain terms, a grade 3 astrocytoma grows faster and behaves more aggressively than grade 2 disease, but it does not yet show the most severe features seen in grade 4 (such as dead tissue called necrosis or abnormal blood-vessel growth). Diagnosis today is integrated: doctors combine what the tumor looks like under the microscope and key molecular tests (for example, IDH mutation status). Radiopaedia+3PMC+3PMC+

Grade III astrocytoma is a cancer that starts from star-shaped brain cells called astrocytes. In 2021, the World Health Organization changed the names and grouped these tumors by their genes. If the tumor has a change (mutation) in the IDH1 or IDH2 gene and looks more aggressive under the microscope (faster cell division, crowding), it is called astrocytoma, IDH-mutant, grade 3. Grade 3 means it grows faster than grade 2 and needs stronger treatment. It is different from glioblastoma, which is always grade 4. Doctors also check markers like ATRX and TP53, and they rule out the 1p/19q codeletion (if present, the tumor is an oligodendroglioma, not an astrocytoma). A special deletion in CDKN2A/B can “upgrade” an IDH-mutant tumor to grade 4. PMC+3PMC+3PMC+3

What’s happening in the body

IDH mutations change how tumor cells use energy and build molecules. This metabolic shift helps the tumor survive and invade nearby brain tissue. Grade 3 tumors show more cell division and abnormal structure than grade 2, so they tend to come back sooner without treatment. Molecular features (IDH status, MGMT promoter methylation, CDKN2A/B status) guide therapy and prognosis; for example, MGMT methylation predicts better response to alkylating chemotherapy like temozolomide. PMC+1

---

Other names you might see

• Astrocytoma, IDH-mutant, CNS WHO grade 3 (current WHO name). PMC

• Anaplastic astrocytoma (historical/habitual term for WHO grade III diffuse astrocytoma). Radiopaedia

• Diffuse astrocytoma, grade III (older phrasing you may see in reports). AJNR

---

Types

1. By modern WHO type and grade: Astrocytoma, IDH-mutant is one tumor type that can be grade 2, 3, or 4. When the same IDH-mutant astrocytoma has increased cell density and clear mitoses (cell divisions) but no microvascular proliferation or necrosis, it is grade 3. This is the entity most people mean by “grade III astrocytoma.” PMC+1

2. By location (practical, symptom-driven): hemispheric (frontal, temporal, parietal, occipital lobes), deep/central (insular, thalamic), cerebellar, or brainstem. Location strongly shapes symptoms and surgical options (this is descriptive rather than a formal WHO subtype). PMC

3. By natural history: some grade 3 tumors arise from a prior lower-grade astrocytoma (“progression”), while others appear de novo at grade 3. Molecular features (for example, IDH mutation with ATRX loss) help place the tumor in the correct family and guide care. PMC

---

Causes

Only a few factors are firmly proven. Many others are genetic predispositions or possible associations with mixed evidence. Below are 20 items grouped by strength, explained in plain language.

A) Strong, well-supported risks

1. High-dose ionizing radiation to the head, especially in childhood (for example, prior therapeutic radiation): clearly increases later glioma risk. PMC+2Nature+2

2. History of childhood cranial radiation for another disease: risk grows with dose and younger age at exposure. PMC

B) Hereditary (germline) predisposition syndromes

These do not mean a tumor will occur, only that lifetime risk is higher.

3. Neurofibromatosis type 1 (NF1) — higher overall glioma risk. PMC

4. Li-Fraumeni syndrome (TP53 germline variants) — broad cancer risk, including gliomas. ASC Publications

5. Lynch syndrome / Constitutional mismatch-repair deficiency (CMMRD) — mismatch-repair gene defects; brain tumors, including gliomas, appear more often. PMC

6. Tuberous sclerosis complex (TSC) — best known for subependymal giant-cell astrocytoma, but glioma risk overall is increased. ASC Publications

7. Rare family clustering / polygenic inherited risk — common low-effect variants and rare high-effect genes each add small amounts of risk in some families. PMC

C) Tumor-related and biological context

8. Progression from a prior grade 2 IDH-mutant astrocytoma — the earlier tumor acquires more aggressive features over time. PMC

9. Specific tumor-cell pathways (IDH mutation with ATRX loss, TP53 alterations) — these are part of the disease biology rather than external “causes,” but they drive how the tumor behaves. PMC

D) Demographic/host factors (associations, not direct causes)

10. Increasing age (adulthood into midlife for grade 3; very old age skews toward grade 4) — overall glioma risk rises with age. PMC

11. Sex and ancestry patterns — some gliomas are slightly more common in males and in certain populations; these are observations, not controllable causes. PMC

E) Possible or debated external factors (evidence mixed or limited)

12. Occupational or environmental chemicals — evidence is inconsistent; no specific chemical is confirmed as a cause. ResearchGate

13. Non-ionizing radiation from mobile phones — large cohort data show no clear link with glioma risk. ScienceDirect+1

14. Air pollution (ultrafine particles) — emerging research suggests a possible link, but this is not established. Frontiers

15. Prior low-to-moderate medical x-ray exposure in adults — overall evidence does not show a consistent increase in glioma risk. Nature+1

16. Immune profile (history of allergies/atopy) — interestingly, allergies seem protective rather than causative; people with atopy often have lower glioma risk. eScholarship

17. General background cosmic radiation — biologically plausible but the added risk in everyday life is very small; high-dose exposures are the concern. PMC

18. Second cancers after chemo-radiation for other tumors — rare; relates mainly to the therapeutic radiation component. The Journal of Neurosurgery

19. Rare inherited PTEN-hamartoma/Cowden-spectrum conditions — gliomas are less common than other tumors in these syndromes but may occur. AACR Journals

20. General lifestyle factors (smoking, diet, alcohol) — to date, no consistent proof of a causal link with glioma risk. eScholarship

---

Common symptoms

1. Headache that gets worse over weeks to months
   Tumor growth and swelling raise pressure inside the skull. Headaches may be worse in the morning or with coughing/straining. Columbia Neurosurgery in New York City

2. Nausea and vomiting
   Also due to raised pressure; vomiting may briefly relieve headache. Columbia Neurosurgery in New York City

3. Seizures
   Seizures can be focal (twitching of one limb, speech arrest) or generalized. They are common in diffuse gliomas, though less often the first symptom in grade 3 than in lower-grade tumors. PMC

4. Weakness or clumsiness on one side (hemiparesis)
   Tumors near the motor pathways cause loss of strength, slower movements, or a “heavy” limb. Medscape

5. Numbness or altered sensation
   Damage to sensory areas causes tingling, reduced touch, or odd sensations on one side. Medscape

6. Speech or language trouble (aphasia)
   Left-hemisphere tumors can cause word-finding problems, slowed speech, or trouble understanding language. Medscape

7. Personality or behavior change
   Frontal-lobe involvement may cause apathy, poor judgment, irritability, or loss of initiative. PMC

8. Memory and thinking problems
   Short-term memory, attention, and planning can decline as networks are disrupted. Cancer Therapy Advisor

9. Vision problems
   Blurry or double vision, or missing parts of side vision (visual field cuts), depend on tumor location and/or raised pressure. Columbia Neurosurgery in New York City

10. Balance and coordination problems
    Cerebellar or pathway involvement causes unsteady walking, poor coordination, or frequent falls. Medscape

11. Dizziness or vertigo
    Can accompany balance issues or arise from brainstem/cerebellar pathways. Medscape

12. Fatigue and daytime sleepiness
    A common, non-specific effect of the tumor, seizures, medicines, and sleep disruption. neurosurgery.weillcornell.org

13. Confusion or slowed processing
    People describe feeling “foggy,” taking longer to think or respond. Cancer Therapy Advisor

14. Head pressure with cough/strain (Valsalva)
    Short spikes in pressure can temporarily worsen pain or vision. Columbia Neurosurgery in New York City

15. Rare spinal symptoms
    If the tumor is in the spinal cord (uncommon for this diagnosis), it may cause back pain, leg weakness, or bowel/bladder issues. neurosurgery.weillcornell.org

---

Diagnostic tests

Doctors combine bedside examination, imaging, pathology, and molecular tests to make an integrated diagnosis and plan care.

A) Physical examination

1. Mental status and language exam
   Short bedside checks of orientation, attention, memory, and language help localize which brain networks are affected and how urgently to act. Merck Manuals

2. Fundoscopic exam for papilledema
   Looking at the optic nerves for swelling can show raised intracranial pressure; presence is highly specific, though sensitivity is limited (absence doesn’t rule out pressure). NCBI+1

3. Motor and sensory screening
   Strength, tone, sensation, and simple screening for neglect identify focal deficits from tumor involvement. Merck Manuals

B) Manual bedside maneuvers

4. Cranial nerve testing
   Eye movements, facial sensation/strength, hearing, palate, tongue, and shoulder checks point to lesion sites and severity. MSD Manuals

5. Visual fields by confrontation
   Simple bedside mapping can detect “missing” portions of vision caused by optic-radiation or occipital lesions. Merck Manuals

6. Reflexes (including plantar/Babinski sign)
   Hyperactive reflexes or an up-going big toe suggest corticospinal tract involvement. Neurology at Washington University

7. Coordination tests (finger-to-nose, heel-to-shin, rapid alternating movements)
   Cerebellar or pathway problems cause intention tremor, dysmetria, or slowed alternating movements. Merck Manuals

8. Gait and balance tests (including Romberg, tandem gait)
   Unsteady gait or Romberg sway shows sensory or cerebellar involvement and overall functional impact. University of Rochester Medical Center

C) Imaging

9. MRI brain with and without gadolinium (the key first test)
   Shows the tumor, its spread, edema, and relationship to critical brain areas. Grade 3 lesions often enhance variably; MRI guides surgery and radiation planning. Radiopaedia

10. Diffusion-weighted MRI (DWI/ADC)
    Helps assess tumor cellularity and identify acute ischemia or abscess when the diagnosis is unclear. Radiopaedia

11. Perfusion MRI (rCBV)
    Elevated relative cerebral blood volume can suggest higher-grade biology and helps separate tumor from treatment effects. Radiopaedia

12. MR spectroscopy (MRS)
    Measures tissue chemicals (for example, high choline, low NAA) that support a tumor diagnosis and help grade assessment. Radiopaedia

13. CT head
    Useful quickly in emergencies (headache, seizure, confusion) to look for mass effect or bleeding when MRI is not immediately available. WebPathology

14. Amino-acid PET (e.g., FET or MET) or FDG-PET if amino-acid PET is unavailable
    Helps map metabolically active tumor, distinguish recurrence from radiation effects, and refine targets for biopsy or radiotherapy. PMC

D) Electrodiagnostic

15. EEG (electroencephalogram)
    Records brain waves to confirm and classify seizures, which are common in diffuse gliomas; EEG guides treatment and sometimes post-op monitoring. Medscape+1

E) Laboratory & pathological tests

16. Stereotactic/open biopsy with histopathology
    The definitive step: tissue shows infiltrating astrocytic tumor with increased cellularity and mitoses, consistent with grade 3 (without necrosis or microvascular proliferation). PMC

17. IDH1/IDH2 mutation testing (IHC/NGS)
    Defines the tumor family (IDH-mutant astrocytoma) and is central to diagnosis and prognosis. PMC

18. ATRX testing (often loss of nuclear expression)
    Supports astrocytoma (vs oligodendroglioma) classification and has prognostic value. PMC

19. 1p/19q codeletion testing
    If codeleted, the tumor is oligodendroglioma, not astrocytoma; if not codeleted (and IDH-mutant), that supports astrocytoma. This distinction changes treatment pathways. PMC

20. MGMT promoter methylation
    A predictive biomarker of benefit from alkylating chemotherapy (like temozolomide) and a prognostic marker in high-grade gliomas. While most robust in glioblastoma, many centers assess it in IDH-mutant grade 3 as part of the molecular profile. PMC

Non-pharmacological treatments (therapies & others)

(Each item gives a brief description, purpose, and basic mechanism—in plain English.)

1. Maximal safe surgical resection
   Purpose: Remove as much tumor as possible while protecting speech and movement.
   Mechanism: Debulking lowers tumor load and pressure; mapping and imaging guide surgeons to avoid critical areas. Greater extent of resection is linked with better outcomes. PMC+1

2. Awake craniotomy with brain mapping
   Purpose: Preserve language/motor function in tumors near “eloquent” cortex.
   Mechanism: Real-time tests (speaking, moving) and electrical mapping help the team remove tumor tissue safely. PMC

3. Neuronavigation + intraoperative imaging (e.g., iMRI/fluorescence)
   Purpose: Make surgery more accurate.
   Mechanism: Live imaging and tracers (like 5-ALA in some centers) highlight tumor tissue and boundaries.

4. External-beam radiotherapy (RT)
   Purpose: Kill remaining cancer cells and reduce recurrence.
   Mechanism: High-energy beams damage tumor DNA; typical dosing for IDH-mutant grade 3 is ~59.4 Gy in 33 fractions with modern planning. PubMed

5. Precision RT planning (ESTRO-EANO guidance)
   Purpose: Target the true tumor region and spare healthy brain.
   Mechanism: Uses MRI (and sometimes amino-acid PET) to shape fields and reduce side effects. Erasmus University Rotterdam

6. Neuro-rehabilitation (physiotherapy)
   Purpose: Improve strength, balance, and independence after surgery or RT.
   Mechanism: Task-specific exercises retrain neural pathways and muscles.

7. Occupational therapy
   Purpose: Make daily activities (dressing, cooking, work) easier and safer.
   Mechanism: Adaptive tools, energy conservation, and home/work modifications.

8. Speech and language therapy
   Purpose: Recover speech, understanding, and swallowing if affected.
   Mechanism: Repetitive, guided speech tasks build alternative brain routes.

9. Cognitive rehabilitation/neuropsychology
   Purpose: Support attention, memory, and planning.
   Mechanism: Strategy training and compensatory tools (planners, apps).

10. Psychological support & psycho-oncology
    Purpose: Ease anxiety, depression, and family stress.
    Mechanism: Counseling, CBT, and caregiver support reduce distress.

11. Palliative care early integration
    Purpose: Improve quality of life from diagnosis—not only at end of life.
    Mechanism: Symptom control (pain, fatigue, mood), goal-setting, and coordination of care. eano.eu

12. Nutrition care (ESPEN)
    Purpose: Prevent weight loss and weakness; support treatment.
    Mechanism: Screening for malnutrition, enough calories/protein, managing taste changes and nausea; avoid high-dose supplements unless advised. ESPEN

13. Seizure safety education
    Purpose: Reduce injury and manage triggers.
    Mechanism: Sleep, medication adherence, and safety planning (e.g., bathing, heights).

14. Fatigue management & graded exercise
    Purpose: Fight cancer-related fatigue.
    Mechanism: Short, regular activity sessions restore stamina.

15. Sleep hygiene
    Purpose: Improve sleep disrupted by steroids, stress, or seizures.
    Mechanism: Regular schedule, light control, caffeine timing.

16. Headache management (non-drug strategies)
    Purpose: Lessen headaches.
    Mechanism: Hydration, regular meals, relaxation, cold/warm packs.

17. Mind-body therapies
    Purpose: Reduce anxiety/pain; improve coping.
    Mechanism: Mindfulness, breathing, guided imagery have modest benefits.

18. Social work & practical support
    Purpose: Address finances, transport, work, and caregiving.
    Mechanism: Resource navigation and paperwork help.

19. Assistive tech (apps, reminders, smart home)
    Purpose: Support memory, safety, and daily routines.
    Mechanism: Alarms, pill boxes, calendars, fall sensors.

20. Clinical-trial participation (non-drug arms/device-based)
    Purpose: Access cutting-edge methods (e.g., advanced imaging guidance).
    Mechanism: Research protocols test new approaches under strict safety rules.

---

Drug treatments

(Each entry gives what it’s for, class, a typical dosing pattern, why, how it works, and common side effects. Doses are typical examples—do not self-dose.)

1. Temozolomide (TMZ)
   Class: Oral alkylating agent. Dose/time: Adjuvant 150–200 mg/m² daily on days 1–5 every 28 days, up to 12 cycles after RT (CATNON).
   Purpose: Standard chemotherapy after RT in IDH-mutant grade 3 astrocytoma.
   Mechanism: Adds methyl groups to DNA (O6-guanine), killing dividing cells—works better when MGMT is methylated.
   Side effects: Low blood counts, nausea, fatigue; rare infections (consider PJP prophylaxis if prolonged). PMC

2. Radiotherapy “with” TMZ (concurrent)
   Note: CATNON found no survival benefit from concurrent TMZ for this group, unlike glioblastoma. Some centers still individualize. Side effects: as above. PubMed

3. PCV regimen (Procarbazine, CCNU/Lomustine, Vincristine)
   Class: Alkylators + vinca alkaloid. Dose/time: e.g., Lomustine 110–130 mg/m² day 1 q6 weeks, Procarbazine days 8–21, Vincristine days 8 & 29 (exact protocols vary).
   Purpose: Alternative in selected cases; more standard for codeleted oligodendroglioma.
   Mechanism: DNA damage + microtubule inhibition.
   Side effects: Myelosuppression (delayed with CCNU), neuropathy (vincristine), nausea; procarbazine has diet/drug interactions (tyramine/MAOI-like). FDA Access Data+1

4. Lomustine (CCNU) single-agent
   Class: Nitrosourea. Dose: 110–130 mg/m² PO once every 6 weeks.
   Purpose: Option at recurrence or when TMZ isn’t appropriate.
   Mechanism: DNA cross-linking.
   Side effects: Delayed low blood counts (need weekly CBCs initially), nausea, rare lung/liver toxicity. FDA Access Data+1

5. Carmustine (BCNU) IV
   Class: Nitrosourea.
   Purpose: Alternative alkylator, often for recurrent disease.
   Mechanism/SE: Similar to lomustine (myelosuppression, nausea).

6. Carmustine wafers (Gliadel®) placed at surgery
   Class: Local chemotherapy implant.
   Purpose: Deliver BCNU directly in the resection cavity (most evidence in GBM; use is center-dependent for high-grade glioma).
   Mechanism: Slow local release to kill residual cells.
   Side effects: Wound issues, edema, seizures; benefits are modest and evidence is mixed. PMC+1

7. Bevacizumab
   Class: Anti-VEGF monoclonal antibody. Dose: Often 10 mg/kg IV every 2 weeks (off-label for grade 3).
   Purpose: At recurrence to reduce edema, improve symptoms, and lower steroid needs (clear survival benefit is unproven in grade 3).
   Mechanism: Blocks VEGF to cut tumor blood vessel leakiness.
   Side effects: High blood pressure, clots/bleeding, wound-healing problems, protein in urine. PMC

8. Irinotecan (often with bevacizumab in recurrence)
   Class: Topoisomerase-I inhibitor.
   Purpose: Palliative regimens in recurrent high-grade glioma.
   Mechanism: Blocks DNA repair in dividing cells.
   Side effects: Diarrhea, low counts.

9. VorAsidenib (Voranigo®)
   Class: Dual IDH1/2 inhibitor. Dose: 40 mg once daily (approved for grade 2 IDH-mutant gliomas; trials are exploring use after definitive therapy in higher grades).
   Purpose: Not standard for grade 3 today; may be considered only in trials/selected contexts.
   Mechanism: Lowers oncometabolite 2-HG; may slow tumor growth.
   Side effects: Elevated liver enzymes, fatigue. Targeted Oncology+1

10. Ivosidenib (IDH1 inhibitor, off-label in glioma)
    Class: Targeted inhibitor. Dose used in reports: 500 mg daily (glioma data are limited; not approved for glioma).
    Purpose: Investigational/real-world use in IDH1-mutant gliomas; discuss in trials.
    Side effects: QT prolongation, liver enzyme rise, fatigue. ASHP+1

11. Dexamethasone
    Class: Corticosteroid.
    Purpose: Rapid relief of brain swelling symptoms (headache, weakness).
    Mechanism: Reduces edema around tumor.
    Dose: Highly individualized; the goal is lowest effective dose for shortest time due to side effects (sleep issues, high sugar, infection, muscle loss). (Guideline principles summarized.)

12. Levetiracetam (and other antiseizure meds)
    Class: Antiepileptic.
    Purpose: Treat seizures. (Note: routine preventive anti-seizure use is not recommended if you’ve never had a seizure.)
    SE: Sleepiness, mood changes. avastin

13. Antiemetics (ondansetron, etc.)
    Purpose: Control nausea from chemo.

14. Pneumocystis (PJP) prophylaxis (e.g., TMP-SMX)
    Purpose: Prevent lung infection during prolonged TMZ plus steroids.

15. G-CSF (filgrastim/pegfilgrastim)
    Purpose: Help white cells recover after alkylators.

16. Proton-pump inhibitors/H₂ blockers
    Purpose: Reduce steroid-related stomach irritation.

17. Pain control (acetaminophen, careful NSAID use)
    Purpose: Headache/neuropathic pain management.

18. Anticoagulation when indicated
    Purpose: Treat or prevent blood clots (brain tumors raise VTE risk).

19. Mirtazapine/SSRIs (when appropriate)
    Purpose: Treat depression/anxiety; can help appetite/sleep.

20. Bowel regimen
    Purpose: Prevent constipation from opioids/steroids/antiemetics.

---

Dietary molecular supplements

Important: Supplements can interact with chemo/RT. Large guidelines advise meeting—but not exceeding—daily requirements and avoiding high-dose antioxidants during active treatment unless your oncology team agrees. Always discuss with your team. ESPEN+2ASC Publications+2

1. Standard multivitamin at RDA levels – supports baseline needs without megadoses. (Avoid high-dose antioxidant blends during RT/chemo.) ESPEN

2. Vitamin D – correct deficiency to support bone/muscle health, especially on steroids; dose per blood test. ESPEN

3. Omega-3 (fish oil) modest dosing – may help appetite/weight maintenance in some cancer patients; check bleeding risk and interactions. ESPEN

4. Oral nutrition supplements (high-protein shakes) – practical calories/protein during fatigue or poor appetite. ESPEN

5. Soluble fiber (oats/psyllium) – helps constipation or loose stools from meds; add slowly with fluids. ESPEN

6. Ginger – may ease mild nausea (tea/capsules); confirm safety with your team. PMC

7. Melatonin (bedtime, low/moderate doses) – sometimes used for sleep; discuss first due to possible interactions. PMC

8. Probiotics – avoid during neutropenia; otherwise discuss for antibiotic-associated diarrhea; evidence varies. ESPEN

9. Magnesium (if low) – corrects deficiency that can worsen cramps/sleep; dose by lab results. ESPEN

10. Thiamine/B-complex at RDA – for poor intake; avoid high doses unless prescribed. ESPEN

---

Immunity-booster / regenerative / stem-cell drug concepts

There are no proven, approved “immune-booster” or stem-cell drugs that cure grade 3 astrocytoma. The options below are investigational—usually available only in clinical trials.

1. Checkpoint inhibitors (pembrolizumab/nivolumab)
   Function: “Releases the brakes” on T-cells. Mechanism: Blocks PD-1/PD-L1; gliomas often resist due to “cold” tumor micro-environment. Dose: Trial-specific. PMC

2. Dendritic-cell vaccines (e.g., DCVax-L concepts)
   Function: Trains the immune system to see tumor antigens. Mechanism: Patient’s immune cells are primed ex vivo and re-infused; evidence is mixed; trial access only. ASC Publications

3. Oncolytic viruses (e.g., DNX-2401, others)
   Function: Engineered viruses infect and kill tumor cells, stirring immune response. Mechanism: Selective replication in cancer cells; early-phase trials in glioma. ESPEN

4. IDH-targeted agents (vorasidenib/ivosidenib)
   Function: Lower the oncometabolite 2-HG to slow tumor biology. Mechanism: IDH1/2 inhibition; approved for grade 2, higher grades under study. Dose: e.g., vorasidenib 40 mg daily. Targeted Oncology

5. Peptide/neoantigen vaccines (IDH-mutant peptides)
   Function: Teach immunity to attack IDH-mutant cells. Mechanism: Peptide presentation to T-cells; trial-only. ASC Publications

6. Adoptive cellular therapies (e.g., TILs/CAR-T for select targets)
   Function: Infuse tumor-reactive immune cells. Mechanism: Engineered or expanded cells target tumor antigens; still experimental in gliomas. PMC

---

Surgeries

1. Stereotactic biopsy – Needle sample through a small hole guided by imaging; used when tumor is deep or surgery is unsafe. Why: Get diagnosis and molecular markers to plan therapy.

2. Craniotomy with tumor resection – Open surgery to remove as much tumor as safely possible. Why: Improve symptoms and outcomes. PMC

3. Awake craniotomy with mapping – Patient performs tasks during surgery while the team maps speech/motor areas. Why: Maximal safe resection near eloquent cortex. PMC

4. Intraoperative MRI / fluorescence-guided surgery – Imaging or dyes highlight tumor to improve completeness. Why: Reduce residual tumor.

5. CSF diversion (ventricular drain/shunt) – For rare cases with high pressure or hydrocephalus. Why: Relieve dangerous pressure.

---

Preventions

There’s no proven way to prevent astrocytoma. Still, these steps reduce avoidable risks and protect overall health:

1. Avoid unnecessary head radiation; use the lowest medical dose needed.

2. Occupational safety if you work around radiation.

3. Genetic counseling if family history suggests a cancer-predisposition syndrome. ASC Publications

4. Healthy lifestyle (exercise, no tobacco, moderate alcohol) for general cancer health.

5. Helmet/seatbelt use—protect brain health (not a tumor prevention, but vital).

6. Manage blood pressure/diabetes to protect brain/body during therapy.

7. Up-to-date vaccines (as allowed during treatment) to reduce infections.

8. Food safety during chemo to avoid infections (wash produce; avoid undercooked foods). ESPEN

9. Discuss supplements with your team (avoid high-dose antioxidants during RT/chemo unless advised). ESPEN+1

10. Know red flags (see next section) and seek early medical care.

---

When to see doctors urgently

• First-ever seizure, or a change in seizure pattern.

• Sudden weakness, speech trouble, confusion, or vision loss.

• Severe, new, or rapidly worsening headache, especially with vomiting or drowsiness.

• Fever, cough, or shortness of breath during chemo/steroids.

• Unusual bleeding/bruising (low platelets) or severe fatigue (low counts).

• Worsening swelling, redness, or drainage from a surgical wound.

---

What to eat and what to avoid

1. Do: Eat small, frequent, high-protein meals (eggs, fish, legumes, yogurt, nuts) to fight weight loss. Avoid: Skipping meals when nauseated—sip calories instead. ESPEN

2. Do: Stay hydrated (water, broths). Avoid: Excess sugary drinks if on steroids (spikes blood sugar). ESPEN

3. Do: Include fruits/vegetables you tolerate (wash well). Avoid: Raw or undercooked meats/eggs; unpasteurized products during chemo. ESPEN

4. Do: Gentle fiber (oats, banana, rice) for loose stools; Avoid: Large amounts of insoluble fiber if diarrhea is active. ESPEN

5. Do: Discuss omega-3 or vitamin D with your oncologist if deficient. Avoid: High-dose antioxidants during RT/chemo unless your team okays them. ESPEN+1

6. Do: If taking procarbazine, follow low-tyramine guidance (your team will give a list). Avoid: Aged cheeses, cured meats, certain beers/wines while on it.

7. Do: Manage steroid appetite with planned snacks. Avoid: Very salty foods if swelling/blood pressure rise.

8. Do: Use ginger or prescribed antiemetics for nausea. Avoid: Strong smells/greasy foods if they trigger nausea. PMC

9. Do: Ask about oral nutrition supplements on tired days. Avoid: Relying on pills/powders instead of real food without dietitian input. ESPEN

10. Do: Bring all supplements to clinic for a safety check. Avoid: Unverified internet remedies. American Cancer Society

---

FAQs

1) Is “grade 3 astrocytoma” the same as “anaplastic astrocytoma”?
Yes—today we say astrocytoma, IDH-mutant, grade 3. The new WHO system uses genetics plus microscope features. PMC

2) What treatment gives the best chance?
Maximal safe surgery → radiotherapy → adjuvant temozolomide up to 12 cycles (CATNON evidence). PMC

3) Do I need chemo during radiation?
For IDH-mutant grade 3, no survival benefit was shown for concurrent TMZ; your team will individualize. PubMed

4) What does MGMT methylation mean?
It predicts better response to alkylating chemo like TMZ. PMC

5) Can these tumors turn into glioblastoma?
They can progress over time; certain molecular changes (e.g., CDKN2A/B deletion) are associated with worse behavior. PMC

6) Are IDH inhibitors like vorasidenib for me?
Vorasidenib is approved for grade 2 IDH-mutant diffuse glioma; use in grade 3 is under study or case-by-case. Ask about trials. Targeted Oncology

7) Will I lose my hair?
RT to the head often causes hair loss in treated areas; some chemo can thin hair.

8) Should I take anti-seizure pills if I’ve never had a seizure?
Guidelines say no routine prophylaxis—but if you’ve had a seizure, treatment is standard. avastin

9) Are supplements safe during treatment?
Use RDA-level supplements only unless your team advises otherwise; avoid high-dose antioxidants during RT/chemo due to possible interference. ESPEN+1

10) Is a special (keto) diet proven to cure this?
No diet cures gliomas; nutrition care aims to keep your strength and weight. ESPEN

11) What dose of radiotherapy is common?
Many centers use about 59.4 Gy in 33 fractions for grade 3 IDH-mutant tumors, with careful target design. PubMed

12) Do mobile phones cause this cancer?
Large modern studies and WHO-commissioned reviews do not show an increased risk. IARC+1

13) What about bevacizumab?
It can relieve swelling and symptoms at recurrence, but survival benefit in grade 3 is unclear. PMC

14) How often will I need scans?
Commonly every 3–4 months at first, then tailored.

15) Can I work or drive?
It depends on seizures, deficits, and local laws; your team will advise.

 

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 16, 2025.